MAGAN FIORELLA: Open Payments
NPI 1720657687 · OWENSBORO, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,562 in 120 payments from 17 companies in 2025. Trend: 2023 $1,354 · 2024 $1,161 · 2025 $1,562
Food & beverage: $1,562
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $360 |
| Novo Nordisk Inc | 13 | $173 |
| PFIZER INC. | 14 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $171 |
| Lilly USA, LLC | 13 | $168 |
| GlaxoSmithKline, LLC. | 6 | $104 |
| Vanda Pharmaceuticals Inc. | 5 | $101 |
| Otsuka America Pharmaceutical, Inc. | 5 | $87 |
| Sumitomo Pharma America, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $45 |
Products named: UBRELVY, CAPLYTA, MOUNJARO, VRAYLAR, NURTEC ODT, REXULTI, PREVNAR 20, JARDIANCE.
Industry payments across KY — which companies pay providers there.
